glutamine has been researched along with ornithylaspartate in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al Mardini, H; Hudson, M; Oppong, K; Record, CO; Rees, CJ | 1 |
| Delcker, A; Mihm, U; Pilatus, U; Raab, P; Rusch, O; Turowski, B; Zanella, FE; Zeuzem, S | 1 |
| Bautista, JD; Grande, L; Ramos Guerrero, RM; Romero Gómez, M; Sánchez Muñoz, D | 1 |
| Gregor, M; Hass, HG; Hösl, F; Kaiser, S; Nägele, T; Seeger, U | 1 |
| Blanco Vela, CI; Poo Ramírez, JL | 1 |
| Butterworth, RF; Canbay, A | 1 |
| Canbay, A; Sowa, JP | 1 |
| Kircheis, G; Lüth, S | 1 |
3 review(s) available for glutamine and ornithylaspartate
| Article | Year |
|---|---|
[New concepts in the physiopathology of hepatic encephalopathy and therapeutic prospects].
Topics: Ammonia; Brain; Brain Edema; Dipeptides; Flumazenil; Glutaminase; Glutamine; Hepatic Encephalopathy; Humans; Hyperammonemia; Inflammation; Intestine, Small; Kidney; Memantine; Models, Molecular; Nerve Tissue Proteins; Nitric Oxide | 2004 |
Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease.
Topics: Dipeptides; Glutamine; Glutathione; Humans; Liver; Non-alcoholic Fatty Liver Disease; Protective Agents | 2019 |
Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
Topics: Ammonia; Animals; Brain; Dipeptides; Glutamic Acid; Glutamine; Hepatic Encephalopathy; Humans; Liver; Liver Cirrhosis; Muscles; Rats; Signal Transduction | 2019 |
1 trial(s) available for glutamine and ornithylaspartate
| Article | Year |
|---|---|
Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial.
Topics: Ammonia; Dipeptides; Double-Blind Method; Electroencephalography; Glutamine; Humans; Liver Cirrhosis, Alcoholic; Middle Aged; Portasystemic Shunt, Transjugular Intrahepatic; Psychometrics | 2000 |
4 other study(ies) available for glutamine and ornithylaspartate
| Article | Year |
|---|---|
Proton MR spectroscopy of neurometabolites in hepatic encephalopathy during L-ornithine-L-aspartate treatment--results of a pilot study.
Topics: Aged; Brain; Creatine; Dipeptides; Female; Glutamic Acid; Glutamine; Hepatic Encephalopathy; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Pilot Projects; Predictive Value of Tests; Reproducibility of Results; Treatment Outcome | 2002 |
[Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)].
Topics: Adult; Ammonia; Brain; Choline; Combined Modality Therapy; Creatinine; Diet, Protein-Restricted; Dipeptides; Energy Metabolism; Female; Follow-Up Studies; Glutamic Acid; Glutamine; Hepatic Encephalopathy; Humans; Infusions, Intravenous; Inositol; Liver Cirrhosis; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neuropsychological Tests; Pilot Projects; Prospective Studies; Reference Values; Statistics as Topic | 2005 |
Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
Topics: Administration, Oral; Ammonia; Dipeptides; Glutamine; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver Cirrhosis; Quality of Life; Severity of Illness Index; Treatment Outcome; Urea | 2011 |
L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease.
Topics: Ammonia; Animals; Antioxidants; Dipeptides; Fatty Liver; Glutamine; Glutathione; Humans; Liver; Non-alcoholic Fatty Liver Disease; Signal Transduction | 2019 |